Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MRIA9, an ATP-competitive inhibitor targeting pan Salt-Inducible Kinases (SIK) and PAK2/3, demonstrates IC50 values of 516 nM, 180 nM, and 127 nM for SIK1, SIK2, and SIK3, respectively [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 598.00 | |
10 mg | Inquiry | $ 954.00 |
Description | MRIA9, an ATP-competitive inhibitor targeting pan Salt-Inducible Kinases (SIK) and PAK2/3, demonstrates IC50 values of 516 nM, 180 nM, and 127 nM for SIK1, SIK2, and SIK3, respectively [1]. |
In vitro | MRIA9 (5 μM) MRIA9 sensitizes SKOV3 cells to paclitaxel treatment through inducing pronounced apoptosis[1].MRIA9 (5 μM) with paclitaxel (2 nM) significantly enhances cell death in HeLa cells[1].MRIA9 strongly impedes centrosome function, causes mitotic spindle mispositioning in ovarian cancer cell lines, prevents the centrosome disjunction during the late G2 phase, and sensitized ovarian cancer cells and patient derived 3D-spheroids to paclitaxel treatment[2]. |
In vivo | MRIA9 shows high oral bioavailability (F = 75-80%)[1]. |
Molecular Weight | 496.92 |
Formula | C24H22ClFN6O3 |
CAS No. | 2750707-05-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MRIA9 2750707-05-0 MRIA-9 MRIA 9 inhibitor inhibit